Lipocine (LPCN) Competitors $2.93 -0.05 (-1.64%) As of 03:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPCN vs. INKT, CVM, COEP, KALA, MNOV, GNTA, INMB, CUE, IMMX, and SLGLShould you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include MiNK Therapeutics (INKT), CEL-SCI (CVM), Coeptis Therapeutics (COEP), KALA BIO (KALA), MediciNova (MNOV), Genenta Science (GNTA), INmune Bio (INMB), Cue Biopharma (CUE), Immix Biopharma (IMMX), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. Lipocine vs. Its Competitors MiNK Therapeutics CEL-SCI Coeptis Therapeutics KALA BIO MediciNova Genenta Science INmune Bio Cue Biopharma Immix Biopharma Sol-Gel Technologies MiNK Therapeutics (NASDAQ:INKT) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Do analysts recommend INKT or LPCN? MiNK Therapeutics currently has a consensus price target of $37.50, indicating a potential upside of 160.24%. Lipocine has a consensus price target of $9.00, indicating a potential upside of 207.06%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more volatility & risk, INKT or LPCN? MiNK Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Is INKT or LPCN more profitable? MiNK Therapeutics' return on equity of 0.00% beat Lipocine's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -227.24% Lipocine N/A -23.59%-21.91% Which has stronger valuation & earnings, INKT or LPCN? Lipocine has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$9.51M-$2.88-5.00Lipocine$11.20M1.42$10K-$0.87-3.37 Does the media prefer INKT or LPCN? In the previous week, MiNK Therapeutics had 3 more articles in the media than Lipocine. MarketBeat recorded 6 mentions for MiNK Therapeutics and 3 mentions for Lipocine. MiNK Therapeutics' average media sentiment score of -0.01 beat Lipocine's score of -0.61 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Do institutionals and insiders believe in INKT or LPCN? 2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryLipocine beats MiNK Therapeutics on 9 of the 14 factors compared between the two stocks. Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPCN vs. The Competition Export to ExcelMetricLipocineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.89M$2.53B$5.76B$9.75BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-3.3722.6331.4526.36Price / Sales1.42535.60431.04155.09Price / CashN/A177.0937.7559.42Price / Book0.935.9510.536.57Net Income$10K$32.94M$3.28B$265.92M7 Day Performance-5.76%-1.64%0.37%0.06%1 Month Performance-10.37%1.93%5.15%1.99%1 Year Performance-18.36%10.64%50.24%20.91% Lipocine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPCNLipocine2.3847 of 5 stars$2.93-1.6%$9.00+207.1%-19.5%$15.89M$11.20M-3.3710Positive NewsINKTMiNK Therapeutics2.736 of 5 stars$14.57-2.2%$37.50+157.4%+86.4%$67.39MN/A-5.0630CVMCEL-SCI0.5262 of 5 stars$10.56+10.9%N/A-71.4%$65.52MN/A-22.0043News CoverageGap DownCOEPCoeptis Therapeutics0.657 of 5 stars$13.65+1.4%N/A+225.3%$64.88MN/A-2.352News CoveragePositive NewsGap UpKALAKALA BIO3.531 of 5 stars$8.78-4.7%$13.00+48.1%+79.5%$64.66M$3.89M-1.2930Positive NewsMNOVMediciNova2.2237 of 5 stars$1.32+0.6%$7.00+430.3%-2.2%$64.37M$1M-5.2810Analyst ForecastGNTAGenenta Science2.3522 of 5 stars$3.50-0.4%$25.00+615.3%-6.1%$64.20MN/A0.007News CoverageGap UpHigh Trading VolumeINMBINmune Bio1.9933 of 5 stars$2.24-7.1%$18.40+721.4%-69.4%$64.07M$50K-0.9010Positive NewsCUECue Biopharma2.6011 of 5 stars$0.82-0.9%N/A+14.5%$63.47M$9.29M-1.4660High Trading VolumeIMMXImmix Biopharma3.3219 of 5 stars$2.10-4.1%$7.00+233.3%+3.2%$63.15MN/A-2.739SLGLSol-Gel Technologies0.7939 of 5 stars$21.00-7.4%N/A+224.0%$63.15M$11.54M-17.0750Gap Down Related Companies and Tools Related Companies INKT Alternatives CVM Alternatives COEP Alternatives KALA Alternatives MNOV Alternatives GNTA Alternatives INMB Alternatives CUE Alternatives IMMX Alternatives SLGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPCN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access